within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDiseaseGord.A02BD03_LansoprazoleAmoxicillinAndMetronidazole;

model LansoprazoleAmoxicillinAndMetronidazole
  extends Pharmacolibrary.Drugs.ATC.A.A02BD03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A02BD03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>This is a triple therapy combination used primarily for the eradication of Helicobacter pylori infection, commonly causing gastric and duodenal ulcers. Lansoprazole is a proton pump inhibitor, amoxicillin is a broad-spectrum penicillin antibiotic, and metronidazole is a nitroimidazole antimicrobial. This combination is approved and widely used globally as a standard first-line treatment for H. pylori infection.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult population, as no direct publication reporting the PK parameters for the fixed-dose combination with ATC code A02BD03 was retrieved. Estimates are based on published PK data for each individual drug given orally in the context of triple therapy.</p><h4>References</h4><ol><li><p>Cheer, SM, et al., &amp; Lamb, HM (2003). Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. <i>Drugs</i> 63(1) 101â€“133. DOI:<a href=\"https://doi.org/10.2165/00003495-200363010-00006\">10.2165/00003495-200363010-00006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12487624/\">https://pubmed.ncbi.nlm.nih.gov/12487624</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end LansoprazoleAmoxicillinAndMetronidazole;
